Database/Guides/AICAR (5-Aminoimidazole-4-Carboxamide Ribonucleotide)
Longevity

AICAR (5-Aminoimidazole-4-Carboxamide Ribonucleotide)

AMPK Activator for Metabolic Optimization, Mitochondrial Biogenesis & Endurance Physiology

๐Ÿ“‹ Full Clinical Guideโฌ‡ Download Guide๐Ÿงฎ Calculator
Dosing Reference
50mg vialSubQ ยท Mitochondrial Function
BAC Water
5mL
Amt / Unit
0.1mg/unit
Dose Range
5-10mg
Draw (units)
50-100 units
Frequency
5-10 days per cycle
Route
SubQ
โ„นAMPK activator. Exercise mimetic. 2-4 cycles/year
Clinical Use Cases
endurancemetabolic optimizationmitochondrial supportexercise performance

1. Clinical Overview of AICAR

Molecule:
AICAR is an AMP analog and intracellular AMP-activated protein kinase (AMPK) activator. It functions as a metabolic signaling molecule that mimics a low-energy cellular state, triggering adaptive pathways involved in energy production, fat oxidation, glucose uptake, and mitochondrial biogenesis.

Classification:

  • AMPK activator
  • Metabolic signaling modulator
  • Exercise-mimetic compound
  • Mitochondrial biogenesis enhancer
Core Concept: AICAR activates many of the same intracellular pathways stimulated by exercise and caloric restriction, without directly increasing adrenergic stimulation.

2. Mechanisms of Action

2.1 AMPK Activation (Primary Mechanism)

AICAR is phosphorylated intracellularly to ZMP, an AMP mimetic that activates AMPK, the master metabolic regulator.

AMPK activation results in:

  • Increased glucose uptake (GLUT4 translocation)
  • Enhanced fatty acid oxidation
  • Suppression of lipogenesis
  • Increased mitochondrial biogenesis
  • Improved insulin sensitivity
Clinical Benefit: Restores metabolic flexibility and cellular energy efficiency.

2.2 Mitochondrial Biogenesis & PGC-1ฮฑ Signaling

Through AMPK โ†’ PGC-1ฮฑ activation, AICAR promotes:

  • Increased mitochondrial number
  • Improved oxidative phosphorylation
  • Enhanced endurance capacity

This pathway is central to longevity and metabolic resilience.

2.3 Exercise-Mimetic Effects

AICAR reproduces several exercise-induced adaptations:

  • Increased oxidative muscle fibers (Type I)
  • Enhanced endurance performance
  • Improved lactate handling
  • Reduced metabolic fatigue

2.4 Glucose & Lipid Metabolism

AICAR:

  • Enhances insulin-independent glucose uptake
  • Reduces hepatic gluconeogenesis
  • Increases fatty acid transport into mitochondria
Clinical Benefit: Improved glycemic control and fat utilization.

2.5 Anti-Inflammatory & Cytoprotective Effects

AMPK activation downregulates:

  • NF-ฮบB signaling
  • Pro-inflammatory cytokines
  • Oxidative stress pathways

3. Evidence-Based Clinical Applications

Important: Human clinical use is off-label and investigational. Most data derive from animal models, cellular studies, and limited human metabolic research.

3.1 Metabolic Syndrome & Insulin Resistance

AICAR supports:

  • Improved insulin sensitivity
  • Reduced ectopic fat accumulation
  • Enhanced metabolic flexibility

3.2 Weight Management & Fat Oxidation

By increasing fat utilization and suppressing lipogenesis, AICAR may support:

  • Fat loss
  • Lean mass preservation
  • Improved metabolic rate

Often used as an adjunct, not monotherapy.

3.3 Endurance & Athletic Performance

Preclinical and early human data demonstrate:

  • Increased endurance capacity
  • Enhanced oxidative muscle phenotype
  • Improved recovery

This has led to WADA prohibition in competitive athletics.

3.4 Longevity & Healthy Aging

AMPK activation is strongly associated with:

  • Lifespan extension in model organisms
  • Improved cellular stress resistance
  • Reduced age-related metabolic decline

3.5 Mitochondrial Dysfunction & Fatigue

Potential benefit in:

  • Chronic fatigue patterns
  • Post-viral fatigue (theoretical)
  • Mitochondrial insufficiency states

4. Administration & Dosing Protocols

AICAR is not intended for continuous daily use long-term. Protocols are typically short cycles with defined off-periods.

4.1 Reconstitution

10 mg vial AICAR

Add:

  • 1 mL bacteriostatic saline โ†’ 10 mg/mL
    or
  • 2 mL saline โ†’ 5 mg/mL

Gently swirl; do not shake.

4.2 Route of Administration

  • Subcutaneous (SC) โ€” preferred
  • Intramuscular (IM) โ€” optional

4.3 Dosing Frameworks (Clinical Use Patterns)

Metabolic Optimization / Longevity Cycle
  • 5โ€“10 mg SC daily
  • 5โ€“10 consecutive days

Cycle frequency: Every 4โ€“8 weeks; typically 2โ€“4 cycles per year

Fat Oxidation / Weight-Management Adjunct
  • 5 mg SC daily ร— 7โ€“10 days
  • Combined with nutritional and lifestyle interventions
Endurance / Mitochondrial Support (Non-Competitive Athletes)
  • 5โ€“10 mg SC daily ร— 5โ€“7 days
  • Not for use in tested athletes

4.4 Post-Cycle Support

Often paired after AICAR cycles with:

  • L-Carnitine (LC-600)
  • NADโบ / mitochondrial support
  • CJC-1295 / Ipamorelin
  • FOXO4-DRI or other longevity peptides (non-concurrent)

5. Clinical Decision Trees

Decision Tree 1 โ€” Candidate Selection

Insulin resistance or metabolic inflexibility? โ†’ Yes

Fat-loss plateau despite diet/exercise? โ†’ Consider

Endurance or mitochondrial support need? โ†’ Consider

Competitive athlete under WADA rules? โ†’ Do NOT use

Active malignancy? โ†’ Avoid

Decision Tree 2 โ€” Cycle Planning

First-time use โ†’ 5 mg ร— 5 days

Good tolerance โ†’ 5โ€“10 mg ร— 7โ€“10 days

Longevity focus โ†’ 1โ€“2 short cycles/year

Fat loss focus โ†’ Combine with nutrition & activity

6. Safety, Contraindications & Monitoring

6.1 Contraindications

  • Active malignancy
  • Pregnancy or breastfeeding
  • Severe hepatic or renal disease
  • Competitive athletes subject to drug testing
  • Hypersensitivity to compound

6.2 Potential Side Effects

Usually dose-dependent and transient:

  • Fatigue or lethargy during cycle
  • Mild nausea
  • Headache
  • Injection-site irritation
  • Hypoglycemia (rare; monitor in diabetics)

6.3 Monitoring Considerations

  • Fasting glucose / insulin
  • Energy and fatigue patterns
  • Body composition
  • Inflammatory markers (optional)
  • Adequate recovery between cycles

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

AICAR (5-Aminoimidazole-4-Carboxamide Ribonucleotide), and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner. Practitioners must exercise independent clinical judgment and assess each patient's individual medical needs, risks, comorbidities, and contraindications prior to implementing any protocol.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions. Any compounding, reconstitution, or administration of peptides must follow appropriate sterile technique and must only be performed by individuals lawfully authorized to handle such materials.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References โ€” AICAR (10 mg) Clinical Reference Guide

AMPK Biology & Metabolic Regulation

1. Hardie, D. G., Ross, F. A., & Hawley, S. A. AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nature Reviews Molecular Cell Biology, 13(4), 251โ€“262 (2012).
2. Hardie, D. G. AMP-activated protein kinase: Maintaining energy balance. Nature Reviews Endocrinology, 10(4), 197โ€“209 (2014).

AICAR Mechanisms & Exercise-Mimetic Effects

3. Corton, J. M., Gillespie, J. G., & Hardie, D. G. AICAR activates AMPK in intact cells. European Journal of Biochemistry, 229(2), 558โ€“565 (1995). (Foundational AICAR-AMPK paper.)
4. Narkar, V. A., et al. AMPK and PPARฮด agonists are exercise mimetics. Cell, 134(3), 405โ€“415 (2008). (Seminal endurance-enhancement study.)

Glucose & Lipid Metabolism

5. Merrill, G. F., et al. AICAR increases glucose uptake and insulin sensitivity. American Journal of Physiology โ€” Endocrinology and Metabolism, 273(6), E1107โ€“E1112 (1997).
6. Bergeron, R., et al. AICAR improves insulin resistance in skeletal muscle. Diabetes, 50(5), 1076โ€“1082 (2001).

Mitochondrial Biogenesis & Longevity

7. Jรคger, S., et al. AMPK regulates PGC-1ฮฑ and mitochondrial biogenesis. Proceedings of the National Academy of Sciences, 104(29), 12017โ€“12022 (2007).
8. Cantรณ, C., & Auwerx, J. AMPK and longevity pathways. Cell Metabolism, 19(1), 1โ€“15 (2014).

Inflammation & Cellular Protection

9. Salminen, A., et al. AMPK signaling in inflammation and aging. Journal of Molecular Medicine, 89(7), 667โ€“676 (2011).
10. O'Neill, L. A. J., et al. Metabolic regulation of immune responses. Nature Reviews Immunology, 16(9), 553โ€“565 (2016).
๐Ÿ”’

Provider Access Required

Create a provider account to read the full clinical guide for AICAR (5-Aminoimidazole-4-Carboxamide Ribonucleotide).

Quick Links